REC.MI
Strong BuyPremium GrowerAI neutralRecordati Industria Chimica e Farmaceutica S.p.A. · Healthcare · Italy · $12.3B
EUR 53.00 -0.2% · close 7 Oct · scored 9 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
Read our full research report on REC.MI (Sep 2026), freeDoes StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Recordati is an Italian specialty pharmaceutical company combining a stable primary care portfolio with a fast-growing rare disease franchise, a model that has delivered high margins and strong cash conversion. Insiders bought about 0.29% of shares in the last 90 days, a positive signal, and the company reported first-half 2026 results. The business is self-funding and suits a higher-rate environment. However, forward earnings estimates fell about 2.1% over four weeks, and the path to growth relies on acquisitions and a few rare disease products, so the upside looks steady rather than asymmetric.
ABOUT RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
Read
Recordati Industria Chimica e Farmaceutica S.p.A. is an international pharmaceutical company focused on the research, development, manufacturing, and marketing of innovative pharmaceuticals, primarily in rare diseases and specialty care. It holds a strong market position in these high-barrier-to-entry sectors, benefiting from strong pricing power and a global commercial presence. Recordati strategically develops and acquires products for niche therapeutic areas, ensuring a focused and high-margin portfolio.
FINANCIAL SUMMARY (EUR)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.6B | 1.9B | 2.1B | 2.3B | 2.6B | 13.5% | 2.7B | 2.8B | 3.0B | 7.5% |
| EPS (EUR) | 1.87 | 1.52 | 1.89 | 2.02 | 2.16 | 3.6% | 2.40 | 2.51 | 2.96 | 17.0% |
| Shares | 209.1M | 205.4M | 206.0M | 206.3M | 204.4M | -2.3% | 204.8M | — | — | — |
| Debt | 992.2M | 1.7B | 1.8B | 2.5B | 2.5B | 25.6% | 2.3B | — | — | — |
| Equity | 1.4B | 1.5B | 1.7B | 1.9B | 1.9B | 8.6% | — | — | — | — |
| Op CF | 491.6M | 461.7M | 485.3M | 569.9M | 596.9M | 5.0% | 648.8M | — | — | — |
| Inv CF | -87.5M | -767.1M | -379.6M | -844.9M | -80.8M | — | — | — | — | — |
| Fin CF | -355.9M | 341.3M | -168.9M | 372.1M | -407.0M | — | — | — | — | — |
Calmer than 95% of stocks we rank over the past year (17% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of REC.MI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A.(you) | $12.3B | 88 | Strong Buy |
| DIA.MI | DiaSorin S.p.A. | $4.4B | 84 | Strong Buy |
| AMP.MI | Amplifon S.p.A. | $3.6B | 78 | Buy |
| STVN | Stevanato Group S.p.A. | $5.9B | 59 | Hold |
| ELN.MI | EL.En. S.p.A. | $1.4B | 85 | Strong Buy |
| PHIL.MI | Philogen S.p.A. | $1.0B | 100 | Strong Buy |
| SFL.MI | Safilo Group S.p.A. | $786M | 95 | Strong Buy |
| GHC.MI | Garofalo Health Care S.p.A. | $542M | 78 | Buy |
| PHN.MI | Pharmanutra S.p.A. | $771M | 71 | Buy |
| GPI.MI | GPI S.p.A. | $474M | 61 | Hold |
Peer medians: ROE 9.1% · P/E 25.2x · Gross margin 50.3%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.